20 results
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
”), elevated liver enzymes, bilirubin, fever, and colitis. Less frequent related SAEs reported in one patient each have included kidney injury, hepatic failure … demand for Apexigen’s products, injury to Apexigen’s reputation, costs to defend the related litigation, a diversion of management’s time
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:03pm
, CRS, elevated liver enzymes, bilirubin, fever, and colitis. Less frequent related SAEs reported in one patient each have included kidney injury … or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:02pm
related SAEs reported in one patient each have included kidney injury, hepatic failure, bleeding, immune-mediated encephalitis, myositis, optic neuritis … , liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion
POS AM
0hqy6tspr 665stu0tky
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
3r19rfw67lkdt7
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
6cc8vvda
9 Sep 22
Prospectus supplement
4:40pm
424B3
crwzkzx th
9 Sep 22
Prospectus supplement
4:38pm
424B3
m74cswc779
6 Jul 22
Prospectus supplement
4:18pm
S-4/A
11x gzpm3f
23 May 22
Registration of securities issued in business combination transactions (amended)
8:00pm
S-4
31ovo8u8
8 Apr 22
Registration of securities issued in business combination transactions
6:37pm
- Prev
- 1
- Next